Abstract: . . .  Doxorubicin 5 1389 53 38 15 Overall* 22 3899 54 40 14 Effect on Progression Rates Thiotepa 3 314 6 5 1 Mitomycin C 3 336 8 4 4 Doxorubicin 3 389 13 15 -2 Overall* 9 1039 9 8 1 *Includes 2 additional trials on ethoglucid and epirubicin, not shown. Page 9 Diagnostic and Treatment Issues in Superficial Bladder Cancer M o n o g r a p h 8 Intravesical Immunotherapy Muhammad S. Choudhury, MD , and Cary N. Robertson, MD Bacillus Calmette-Guérin (BCG) is considered the gold standard for initial treatment of . . .
. . .  Likewise, although the J82 cell line did not appear to be sensitive to either BCG or interferon alfa-2b alone, the combination of BCG plus interferon alfa-2b had an antiproliferative effect. Efficacy Based on the clinical rationale for combining BCG and interferon alfa-2b, a number of centers have investigated this combination in patients with superficial bladder cancer . These studies suggest that BCG/int . . .
. . .  However, observations that intra- vesical interferon alfa-2b therapy has substantial activity in up to 20% of patients who failed BCG therapy 20,21 are extremely encouraging and suggest that one important application of interferon alfa-2b is in the treatment of BCG failures. Safety Intravesical interferon alfa is associated with minimal local toxicity. The most common adverse events are mild fever and flulike symptoms, which occur in <30% of treated patients. 22 No dose-limiting toxicity has been . . .
. . .  Overall* 22 3899 54 40 14 Effect on Progression Rates Thiotepa 3 314 6 5 1 Mitomycin C 3 336 8 4 4 Doxorubicin 3 389 13 15 -2 Overall* 9 1039 9 8 1 *Includes 2 additional trials on ethoglucid and epirubicin, not shown. Page 9 Diagnostic and Treatment Issues in Superficial Bladder Cancer M o n o g r a p h 8 Intravesical Immunotherapy Muhammad S. Choudhury, MD , and Cary N. Robertson, MD Bacillus Calmette-Guérin (BCG) is considered the gold standard for initial treatment of superficial bladder cancer . . .
. . .  alfa-2b alone, the combination of BCG plus interferon alfa-2b had an antiproliferative effect. Efficacy Based on the clinical rationale for combining BCG and interferon alfa-2b, a number of centers have investigated this combination in patients with superficial bladder cancer . These studies suggest that BCG/int . . .
. . .  alone, the combination of BCG plus interferon alfa-2b had an antiproliferative effect. Efficacy Based on the clinical rationale for combining BCG and interferon alfa-2b, a number of centers have investigated this combination in patients with superficial bladder cancer . These studies suggest that BCG/int . . .
--3000,6,250,2964,54214